Table 1.
Characteristics of the Study Population According to the Consumption of BZDs and Z-Drugs
| Non-BZDs Users (n = 84.652) | BZDs Users (n = 83.138) | P | |
|---|---|---|---|
| Age, mean (SD) | 63.0 (12.5) | 72.8 (14.6) | <.001 |
| Women, n (%) | 47 021 (55.6%) | 50 064 (60.2%) | <.001 |
| Hypertension, n (%) | 29 832 (35.2%) | 44 266 (53.2%) | <.001 |
| Diabetes, n (%) | 12 112 (14.3%) | 18 162 (21.9%) | <.001 |
| Dislipemia, n (%) | 25 288 (29.9%) | 33 187 (39.9%) | <.001 |
| Cardiopathy, n (%) | 3022 (3.6%) | 6824 (8.2%) | <.001 |
| Depression, n (%) | 3443 (4.1%) | 13 546 (16.3%) | <.001 |
| Anxiety, n (%) | 4856 (5.7%) | 20 813 (25.0%) | <.001 |
| Sleep disturbances, n (%) | 1566 (1.9%) | 2455 (3.0%) | <.001 |
| Affective disorders, n (%) | 698 (0.8%) | 3118 (3.8%) | <.001 |
| Dementia, n (%) | 1503 (1.8%) | 4353 (5.2%) | <.001 |
Abbreviations: BZD, benzodiazepine.